Profile data is unavailable for this security.
About the company
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
- Revenue in HKD (TTM)0.00
- Net income in HKD-1.02bn
- Incorporated2018
- Employees175.00
- LocationKintor Pharmaceutical LtdNo. 20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
- Phone+86 51 262639909
- Websitehttps://www.kintor.com.cn/
More ▼